Hormone Optimisation Therapy + Peptide Therapy
Documented synergy between Hormone Optimisation Therapy and Peptide Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →Precise hormonal balance for vitality and longevity
Definition and how it works: Hormone optimisation therapy (TRT/HRT) goes beyond treating clinical deficiencies: it aims to maintain hormone levels in the optimal range (not merely within the standard reference range) to maximise quality of life, body composition, cognitive function and longevity. It encompasses testosterone, oestradiol, progesterone, DHEA, pregnenolone, thyroid and growth hormone, always guided by comprehensive biomarker analysis.
Hormone optimisation therapy (TRT/HRT) goes beyond treating clinical deficiencies: it aims to maintain hormone levels in the optimal range (not merely within the standard reference range) to maximise quality of life, body composition, cognitive function and longevity. It encompasses testosterone, oestradiol, progesterone, DHEA, pregnenolone, thyroid and growth hormone, always guided by comprehensive biomarker analysis.
Origin and history
The first therapeutic use of testosterone extracts was in 1935. Oestrogen therapy for menopause became widespread in the 1960s. Hormone optimisation medicine as a specific discipline emerged through the work of Abraham Morgentaler and Thierry Hertoghe in the 1990s–2000s.
1. Comprehensive hormone panel Total/free testosterone, SHBG, oestradiol, LH, FSH, DHEA-S, IGF-1, TSH, T3/T4, cortisol.
2. Optimisation consultation Interpretation by a physician specialising in hormonal longevity medicine. Goal definition.
3. Prescription and delivery method TRT: topical gel, injectable or subcutaneous pellet. HRT: patch, gel or bioidentical capsule.
4. Titration Progressive dose adjustment every 6–8 weeks with control blood work.
5. Quarterly follow-up Hormone panel, haematocrit, PSA (men), mammography/endometrium (women) per protocol.
| Equipment | Brand / Model | Technical detail |
|---|---|---|
| Automated hormone analyser | Roche Elecsys / Abbott Architect | Measurement of sex hormones, IGF-1, DHEA and metabolic biomarkers. |
| Bioidentical testosterone | Androgel / Testogel / Compounding pharmacy | Transdermal gel with bioidenticals for precision TRT and HRT. |
Clinics on LongevityMap declare their exact equipment for objective scoring.
Precise hormonal balance for vitality and longevity
€150–400 per consultation + blood work
Initial consultation + quarterly follow-up
Prices vary by clinic, equipment and practitioner experience. LongevityMap compares price and quality so you always make the best decision.
Documented synergy between Hormone Optimisation Therapy and Peptide Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →Documented synergy between Hormone Optimisation Therapy and Biomarker Testing. Canonical combination in literature · see protocol and evidence.
View comparison →Documented synergy between Hormone Optimisation Therapy and NAD+ IV Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →We are collecting signed consents under GDPR Art. 9.2.a. First verified testimonials will appear once the first real clinics are onboarded (Q4 2026).
The WHI study (2002) generated controversy around HRT, but subsequent reviews confirm that early initiation of therapy (before age 60 or within 10 years of menopause) reduces cardiovascular risk and mortality. Meta-analyses in the Journal of Clinical Endocrinology & Metabolism confirm that TRT in men with hypogonadism improves cardiovascular, metabolic and quality-of-life markers.
Meta-analysis 23 RCTs (n=9,280 men with testosterone deficiency, mean age 64.6): TRT does NOT increase mortality or major cardiovascular events vs placebo, but SIGNIFICANTLY INCREASES cardiac arrhythmia incidence (RR 1.53; 95% CI 1.20-1.97; p<0.01). Cardiac monitoring recommended.
2025 WHI secondary analysis (n=27,347 postmenopausal women): menopausal hormone therapy in women with moderate-severe vasomotor symptoms at age <60 was associated with reduced cardiovascular risk; in women ≥70 the risk-benefit balance reverses. Age at initiation critical.
Lancet Healthy Longevity 2025 SR/MA (10 studies, n=1,016,055): NO significant association found between MHT use and risk of mild cognitive impairment or dementia. Subgroup analyses (timing, duration, type) also showed no significant effects.
2026 Alzheimer's & Dementia RCT (10-year post-MHT follow-up): NEITHER oral CEE NOR transdermal estradiol (4 years) modified amyloid-β biomarkers or brain MRI structure vs placebo. Supports long-term safety of short-term MHT use on brain health.
Last bibliographic review: 2026-03-28.
Exogenous TRT suppresses sperm production. For men wishing to preserve fertility, alternatives such as hCG or clomiphene stimulate endogenous production without suppressing it.
Initial effects (energy, libido, mood) are typically felt within 3–6 weeks. Changes in body composition (muscle/fat) require 3–6 months. Full optimisation may take up to 12 months.
It depends on the indication. In established hypogonadism, therapy is usually indefinite. For longevity optimisation, it is periodically reassessed with blood work. The decision is always medical and individualised.
Tell us your goal and budget. We cross-reference 500+ clinical parameters and generate 3 personalised plans with Hormone Optimisation Therapy.
Generate My Protocol for freeLongevityMap content is for informational and educational purposes only. It does not constitute personalised medical advice. Always consult a healthcare professional before starting any treatment. Our team · Methodology